Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

multiple sclerosis

25th Jun 2025

Plain language summary: how following multiple sclerosis medication prescriptions affects disease flare-ups, physical limitations, and medical expenses

20th May 2025

Health outcomes and healthcare service use in older adults with and without multiple sclerosis: a plain language summary

13th May 2025

Shared decision-making for multiple sclerosis using the MS-SUPPORT tool: a plain language summary

12th Aug 2024

Multiple sclerosis patients co-design a tool to measure physical functioning and its impact on daily life: a plain language summary

This summary explains the findings of a recent study that compared different questionnaires used by doctors to measure levels of fatigue in people with multiple sclerosis (MS). The aim of the study was to find out which questionnaire doctors should use to measure fatigue in people with MS in the future.Fatigue, which can be described as the overwhelming feeling of tiredness or exhaustion, is a very common symptom of MS. For the majority of people with MS, fatigue is one of the worst symptoms of MS, so it is essential that doctors can measure it accurately. Currently, people with MS are asked to complete questionnaires so that their care team can see the effect of fatigue on their day-to-day lives. There are many questionnaires that are used to measure fatigue in people with MS. It would be valuable to come to an agreement, based on evidence from research like this study, on which questionnaire is the most appropriate for measuring fatigue in both research and healthcare settings.This study compared a questionnaire called the PROMIS® Fatigue (MS) 8a, referred to throughout this summary as the PROMIS® MS Fatigue Short Form, with two of the most commonly used questionnaires: the Fatigue Severity Scale (FSS) and the Modified Fatigue Impact Scale (MFIS). The questionnaires were compared to see which one should be recommended to doctors for measuring fatigue in people with MS.
30th Apr 2024

Which questionnaire should doctors use to measure fatigue in people with multiple sclerosis (MS)? A plain language summary

Previous studies have shown that people living with multiple sclerosis (MS) treated with cladribine tablets have fewer relapses (where new symptoms occur or existing symptoms get worse for 24 hours or more) and delayed disability progression (slowing down of the disease getting worse). The CLASSIC-MS study looked at the long-term effectiveness of treatment with cladribine tablets in people living with MS who had taken part in the original CLARITY and CLARITY Extension clinical studies
10th Aug 2023

Plain language summary: the CLASSIC-MS study assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis

This summary explains the findings from a recent investigation that combined the results of over 1000 people from three clinical studies to understand the safety of evobrutinib.Evobrutinib is an oral medication (taken by mouth), being researched as a potential treatment for multiple sclerosis (MS). This medication was also investigated in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).Over 1000 people have taken evobrutinib as part of three separate phase 2 clinical studies. These studies looked at how much of the drug should be taken, how safe the drug is, and how well it might work for treating a certain medical condition.
27th Jun 2023

Plain Language Summary: what can clinical studies tell us about evobrutinib, a potential treatment for multiple sclerosis

Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries.Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked atreal-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad®) compared with other oral treatments.
8th Jun 2023

Plain Language Summary: Results from the MSBase registry looking at the effectiveness of cladribine tablets for multiple sclerosis

1st Mar 2023

A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy